Cytek Biosciences, Inc. (CTKB)

NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04

$4.700.00%

Close 2026-09-04 · 1-day change

QuarterlyIQ Insights · CTKB

Financials

Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.

Income Statement

Period

View

Order

Figures in millions of USD, except per-share and ratios.

	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenues
Revenues	206.7	201.5	200.5	193.0	3.0	2.2	0.7
Total Revenues	—	—	—	193.0	3.0	2.2	0.7
Cost of Revenues	96.7	97.0	89.3	83.6	63.1	48.8	41.1
Gross Profit	110.0	104.5	111.1	109.4	—	—	—
Operating Expenses & Income
R&D Expenses	37.3	36.5	39.4	44.2	34.9	24.4	13.7
Operating Income	(44.6)	(40.4)	(20.5)	(27.8)	(1.8)	9.2	13.7
Earnings from Continuing Operations
Interest Expense	—	0.5	—	2.1	2.6	1.7	0.3
Interest & Investment Income	2.8	2.2	5.1	6.4	4.6	0.0	0.1
Net Interest Expenses	—	—	—	(4.3)	(2.0)	1.7	0.2
Other Non-Operating Income / Expenses	3.8	10.5	14.8	12.1	3.1	(3.2)	0.8
EBT, Incl. Unusual Items	—	(29.8)	(5.7)	(15.7)	1.3	5.9	14.4
Income Tax Expense	39.8	36.7	0.3	(3.6)	(1.2)	2.9	(5.0)
Net Income
Minority Interest	—	—	—	0.0	(0.1)	0.0	0.0
Net Income	—	(66.5)	(6.0)	(12.1)	2.5	3.0	19.4
Per Share
Basic EPS	—	—	—	(0.09)	0.02	0.00	0.11
Diluted EPS	—	—	—	(0.09)	0.02	0.00	0.10
Revenue per Share	1.60	—	—	—	—	—	—
Basic Weighted Avg Shares	129.5	127.7	130.6	135.3	134.5	76.7	29.1
Diluted Weighted Avg Shares	129.5	127.7	130.6	135.3	138.6	81.5	32.6
Supplemental
EBITDA	—	(32.8)	(13.3)	(21.8)	0.7	10.4	14.3
EBIT	(44.6)	(40.4)	(20.5)	(27.8)	(1.8)	9.2	13.7
Effective Tax Rate	—	—	—	22.7%	-97.1%	49.0%	-34.5%

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.